BDNF plasma levels variations in major depressed patients receiving duloxetine
- 287 Downloads
It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 % of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.
KeywordsBDNF Depression Duloxetine Neuroplasticity Neuroendocrine immunity
Authors have no acknowledgement to state. The authors received any financial support for this paper.
Conflict of interests
Authors have no conflict of interest to declare.
- 4.Martino M, Rocchi G, Escelsior A, Fornaro M (2012) Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr Neuropharmacol 10 [ahead of print]Google Scholar
- 6.Rojas PS, Fritsch R, Rojas RA, Jara P, Fiedler JL (2011) Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res 189(2):239–245. doi: 10.1016/j.psychres.2011.04.032 CrossRefPubMedGoogle Scholar
- 7.Basterzi AD, Yazici K, Aslan E, Delialioglu N, Tasdelen B, Tot Acar S, Yazici A (2009) Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 33(2):281–285. doi: 10.1016/j.pnpbp.2008.11.016 CrossRefPubMedGoogle Scholar
- 8.Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43(3):247–254. doi: 10.1016/j.jpsychires.2008.03.014 CrossRefPubMedGoogle Scholar
- 14.APA (1994) Diagnostic and statistical manual for mental disorders, 4th edn. American Psychiatrich Association, WashingtonGoogle Scholar
- 18.Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G (2011) Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr Dis Treat 7:51–56. doi: 10.2147/NDT.S16382 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Fornaro M, Bandini F, Ogliastro C, Cordano C, Martino M, Cestari L, Escelsior A, Rocchi G, Colicchio S, Perugi G (2011) Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background? J Affect Disord 135(1–3):154–159. doi: 10.1016/j.jad.2011.07.013 CrossRefPubMedGoogle Scholar